Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 11, Issue 5, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-12
DOI
10.1038/s41419-020-2567-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
- (2019) Christine Ménétrier-Caux et al. Journal for ImmunoTherapy of Cancer
- Microtubule-Targeting Drugs: More than Antimitotics
- (2019) Roma Kaul et al. JOURNAL OF NATURAL PRODUCTS
- Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
- (2019) Owen A. O’Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
- (2019) Alexis Fong et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations
- (2019) Angela Flavia Serpico et al. Cancers
- Orchestration of the spindle assembly checkpoint by CDK1‐cyclin B1
- (2019) Daniel Hayward et al. FEBS LETTERS
- Recent advances in microtubule-stabilizing agents
- (2018) Ya-Nan Cao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors
- (2018) Susanne Liewer et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The impact of mitotic errors on cell proliferation and tumorigenesis
- (2018) Michelle S. Levine et al. GENES & DEVELOPMENT
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton
- (2018) Michel O. Steinmetz et al. TRENDS IN CELL BIOLOGY
- Nuclear envelope assembly defects link mitotic errors to chromothripsis
- (2018) Shiwei Liu et al. NATURE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Site occupancy calibration of taxane pharmacology in live cells and tissues
- (2018) Javier J. Pineda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fighting tubulin-targeting anticancer drug toxicity and resistance
- (2017) Roberta Visconti et al. ENDOCRINE-RELATED CANCER
- Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic
- (2017) Jue Shi et al. ENDOCRINE-RELATED CANCER
- EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis
- (2017) Lucy S.K. Walker IMMUNOLOGY LETTERS
- G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells
- (2017) Danî Kalsbeek et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Taxol®: The First Microtubule Stabilizing Agent
- (2017) Chia-Ping Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
- (2017) Takeo Fujii et al. INVESTIGATIONAL NEW DRUGS
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- Anti-mitotic agents: Are they emerging molecules for cancer treatment?
- (2017) Larissa Siqueira Penna et al. PHARMACOLOGY & THERAPEUTICS
- Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
- (2017) Vinay Prasad et al. SEMINARS IN ONCOLOGY
- Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?
- (2017) T. J. Mitchison et al. Open Biology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Microtubule destabilising agents: far more than just antimitotic anticancer drugs
- (2016) Darcy Bates et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
- (2016) Roberta Visconti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs
- (2015) R Visconti et al. CELL DEATH AND DIFFERENTIATION
- Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins
- (2015) Marianne S. Poruchynsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nab-paclitaxel: A flattering facelift
- (2014) A. Viúdez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- How Taxol/paclitaxel kills cancer cells
- (2014) Beth A. Weaver MOLECULAR BIOLOGY OF THE CELL
- Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C
- (2014) Katharine L. Sackton et al. NATURE
- Cytotoxicity of Paclitaxel in Breast Cancer Is due to Chromosome Missegregation on Multipolar Spindles
- (2014) L. M. Zasadil et al. Science Translational Medicine
- Kinesin Spindle Protein (KSP) Inhibitors in Combination with Chemotherapeutic Agents for Cancer Therapy
- (2013) Hualong Song et al. ChemMedChem
- Mitosis and apoptosis: how is the balance set?
- (2013) Caroline H Topham et al. CURRENT OPINION IN CELL BIOLOGY
- Mitosis-targeting therapies: a troubleshooting guide
- (2013) Elena Doménech et al. CURRENT OPINION IN PHARMACOLOGY
- Interphase microtubules: chief casualties in the war on cancer?
- (2013) Angela Ogden et al. DRUG DISCOVERY TODAY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
- (2012) E. Komlodi-Pasztor et al. CLINICAL CANCER RESEARCH
- DNA breaks and chromosome pulverization from errors in mitosis
- (2012) Karen Crasta et al. NATURE
- Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells
- (2012) Shan Wan et al. PLoS One
- Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
- (2012) L. Sun et al. SCIENCE
- Fcp1-dependent dephosphorylation is required for M-phase-promoting factor inactivation at mitosis exit
- (2012) Roberta Visconti et al. Nature Communications
- Mitosis is not a key target of microtubule agents in patient tumors
- (2011) Edina Komlodi-Pasztor et al. Nature Reviews Clinical Oncology
- Mitotic catastrophe: a mechanism for avoiding genomic instability
- (2011) Ilio Vitale et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
- (2010) Xing Zeng et al. CANCER CELL
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now